Literature DB >> 11738849

Cerebrolysin therapy in Rett syndrome: clinical and EEG mapping study.

N Gorbachevskaya1, V Bashina, V Gratchev, A Iznak.   

Abstract

Based on the suggestion that nerve growth factor plays a core role in the brain maturation process, which is altered in Rett syndrome, we investigate the influence of Cerebrolysin--the brain-derived peptidergic drug - on motor and higher cortical functions in Rett syndrome girls. The open pilot study was performed on nine Rett syndrome girls (aged from 2 years and 2 months to 7 years and 6 months) at stage 3 of the illness, and included both clinical and quantitative EEG evaluations before and after Cerebrolysin treatment. After Cerebrolysin treatment, increases in the behavioral activity, attention level, motor functions, and non-verbal social communication have been shown in Rett syndrome patients. EEG parameters after Cerebrolysin treatment also changed towards normal values, indicating an improvement of the brain functional state. EEG changes included: decrease of theta activity over all cortical regions, increase of beta activity in the frequency band 13-15 Hz, and some restoration of the occipital alpha rhythm (in the narrow 8-9 Hz band). The data obtained suggested possible perspectives of Cerebrolysin in complex therapy of Rett syndrome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11738849     DOI: 10.1016/s0387-7604(01)00349-7

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  7 in total

1.  Neurotrophic effects of Cerebrolysin in the Mecp2(308/Y) transgenic model of Rett syndrome.

Authors:  Edith Doppler; Edward Rockenstein; Kiren Ubhi; Chandra Inglis; Michael Mante; Anthony Adame; Leslie Crews; Monika Hitzl; Herbert Moessler; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2008-07-04       Impact factor: 17.088

Review 2.  Neurobiologically-based treatments in Rett syndrome: opportunities and challenges.

Authors:  Walter E Kaufmann; Jennifer L Stallworth; David B Everman; Steven A Skinner
Journal:  Expert Opin Orphan Drugs       Date:  2016-09-10       Impact factor: 0.694

Review 3.  Key issues in Rett syndrome: emotional, behavioural and autonomic dysregulation (EBAD) - a target for clinical trials.

Authors:  Jatinder Singh; Paramala Santosh
Journal:  Orphanet J Rare Dis       Date:  2018-07-31       Impact factor: 4.123

Review 4.  Reviewing Evidence for the Relationship of EEG Abnormalities and RTT Phenotype Paralleled by Insights from Animal Studies.

Authors:  Kirill Smirnov; Tatiana Stroganova; Sophie Molholm; Olga Sysoeva
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

5.  Heightened Delta Power during Slow-Wave-Sleep in Patients with Rett Syndrome Associated with Poor Sleep Efficiency.

Authors:  Simon Ammanuel; Wesley C Chan; Daniel A Adler; Balaji M Lakshamanan; Siddharth S Gupta; Joshua B Ewen; Michael V Johnston; Carole L Marcus; Sakkubai Naidu; Shilpa D Kadam
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240

6.  Safety and Efficacy of Cerebrolysin in Infants with Communication Defects due to Severe Perinatal Brain Insult: A Randomized Controlled Clinical Trial.

Authors:  Sahar M A Hassanein; Shaymaa M Deifalla; Moustafa El-Houssinie; Somaia A Mokbel
Journal:  J Clin Neurol       Date:  2015-09-11       Impact factor: 3.077

Review 7.  VIII World Rett Syndrome Congress & Symposium of rare diseases, Kazan, Russia.

Authors:  Ivan Y Iourov; Svetlana G Vorsanova; Yuri B Yurov; Thomas Bertrand
Journal:  Mol Cytogenet       Date:  2018-12-24       Impact factor: 2.009

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.